{
    "other_tests": [
        {
            "procedure_name": "Bergman-modified minimal model frequent sampling iv glucose tolerance test (FSIGT)",
            "date": "Not specified",
            "findings": "Si was markedly reduced at baseline at 1.45 310^24 min^-1 (mU/mL); fasting insulin was 28.9 mU/L. Baseline showed an exaggerated insulin response.",
            "changes_over_time": "As a result of rhIGF-I therapy, Si improved dose-dependently into the normal range; after 6 months on a dose of 80 mg/kg, Si was 4.39 310^24 min^-1. Fasting insulin decreased to 7.5 mU/L after 6 months."
        },
        {
            "procedure_name": "Dual-energy x-ray absorptiometry",
            "date": "Not specified",
            "findings": "Baseline lumbar BMD was 0.58 g/cmÂ² with a severe reduction compared to age-matched controls.",
            "changes_over_time": "BMD increased by 17% after 12 months of therapy; bone mineral apparent density (BMAD) increased by 7%."
        },
        {
            "procedure_name": "Auxological measurements",
            "date": "Not specified",
            "findings": "Pretreatment height was 120.4 cm with a height velocity of 3.8 cm/yr.",
            "changes_over_time": "Height increased to 126.9 cm after 12 months, with height velocity increasing to 7.3 cm/yr on 80 mg/kg/day of rhIGF-I."
        },
        {
            "procedure_name": "Markers of bone turnover measurement",
            "date": "Not specified",
            "findings": "Mean serum osteocalcin was 8.3 ng/mL pretreatment and increased to 21.7 ng/mL after 6 months. Mean bone specific alkaline phosphatase was 36.5 U/L pretreatment and increased to 82.2 U/L after 6 months.",
            "changes_over_time": "At 12 months, osteocalcin dropped to 12.9 ng/mL and alkaline phosphatase decreased to 38.5 U/L."
        }
    ]
}